Product Center
The study on pregnant women receiving quadrivalent influenza virus subunit vaccine has successfully completed key enrollment
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-02-10
- Views:
(Summary description)Recently, the vaccination of pregnant women with quadrivalent influenza virus subunit vaccine (HRK-X®) was officially launched on March 1, 2025, jointly carried out by the First Affiliated Hospital of Chongqing Medical University and the Disease Prevention and Control Center of Yuzhong District, Chongqing ®） The safety and immune efficacy research of this groundbreaking clinical study has made significant progress - all participants have successfully completed the enrollment, marking the beginning of a new stage.
The study on pregnant women receiving quadrivalent influenza virus subunit vaccine has successfully completed key enrollment
(Summary description)Recently, the vaccination of pregnant women with quadrivalent influenza virus subunit vaccine (HRK-X®) was officially launched on March 1, 2025, jointly carried out by the First Affiliated Hospital of Chongqing Medical University and the Disease Prevention and Control Center of Yuzhong District, Chongqing ®） The safety and immune efficacy research of this groundbreaking clinical study has made significant progress - all participants have successfully completed the enrollment, marking the beginning of a new stage.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-02-10 09:09
- Views:
Recently, the vaccination of pregnant women with quadrivalent influenza virus subunit vaccine (HRK-X®) was officially launched on March 1, 2025, jointly carried out by the First Affiliated Hospital of Chongqing Medical University and the Disease Prevention and Control Center of Yuzhong District, Chongqing ®） The safety and immune efficacy research of this groundbreaking clinical study has made significant progress - all participants have successfully completed the enrollment, marking the beginning of a new stage.
The successful completion of this enrollment work fills the gap in clinical data of influenza vaccines for pregnant women in China, and provides solid scientific evidence from the Chinese population for the international consensus that "influenza vaccination during pregnancy is safe".
Influenza, as a highly contagious acute respiratory disease, causes seasonal outbreaks every year and poses a persistent threat to special populations. Pregnant women may experience physiological changes in their cardiovascular and respiratory systems during pregnancy, resulting in a special immune status. They not only have a higher risk of infection and more severe symptoms, but may also progress to severe illness or even death. Meanwhile, high fever caused by influenza can also increase the risk of adverse pregnancy outcomes such as premature birth.
Although both the World Health Organization and the Chinese Center for Disease Control and Prevention have explicitly listed pregnant women as a priority group for influenza vaccination, there has been a lack of clinical data on vaccines for this group in China for a long time. Some vaccine instructions still list pregnant women as contraindicated, resulting in a significantly lower vaccination rate for pregnant women in China compared to international levels. In addition, infants under 6 months of age cannot receive the influenza vaccine, making maternal antibodies the only key immune barrier to protect newborns. These practical factors collectively constitute a severe challenge in the current prevention of maternal and infant influenza.
To this end, the First Affiliated Hospital of Chongqing Medical University and the Disease Prevention and Control Center of Yuzhong District, Chongqing have conducted significant clinical studies. This clinical study strictly follows a randomized, double-blind, and scientifically standardized research design, systematically evaluating the safety, immunogenicity, and maternal antibody protective effect of the quadrivalent influenza virus subunit vaccine in pregnant women. The aim of this study is to provide clear clinical evidence for pregnant women to receive influenza vaccines, increase the number of suitable populations, and solve the practical dilemma of "wanting to receive the vaccine but having no basis, and medical staff being afraid to recommend it". It not only helps pregnant women obtain direct protection during pregnancy, but also establishes a key immune defense line for fetuses and infants aged 0-6 months through maternal antibodies, thus safeguarding maternal and infant health and safety from the source.
Relevant information
-
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going globalOn March 13, 2026, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines in Taizhou. Both parties announced that they will jointly promote the development of the influenza virus subunit vaccine independently developed by Ab&B Bio and set sail to the sea. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field. - Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi 03-04
- Announcement of Pre increase in Performance for 2025 Released 02-26
- Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase 02-16
- The study on pregnant women receiving quadrivalent influenza virus subunit vaccine has successfully completed key enrollment 02-10
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
